继续使用利特昔替尼至48周可维持斑秃患者毛发再生:ALLEGRO 2b/3期事后分析
该事后分析评估利特昔替尼持续治疗至48周的疗效与安全性。24周达到SALT≤20和≤10应答的患者中,分别≥85%和≥68%维持应答至48周;24周未达标者中22%-34%和20%-26%分别达到SALT≤20和≤10。安全性各亚组相似。
要点
- 24周SALT≤20应答者中≥85%维持至48周
- 24周SALT≤10应答者中≥68%维持至48周
- 24周未达标者继续治疗至48周,最多约三分之一可达标
核心结论
- 24周有应答的斑秃患者继续利特昔替尼治疗至48周可维持毛发再生。
- 24周未达目标疗效者继续治疗至48周,最多约三分之一可达到应答。
研究设计与样本
- ALLEGRO 2b/3期试验的事后分析,患者年龄≥12岁,每日接受利特昔替尼(±4周负荷剂量):200/50 mg、200/30 mg、50 mg或30 mg。
- 基于24周SALT评分≤20和≤10评估临床应答,并评估应答维持至48周;24周无应答者评估至48周的应答。
主要发现
- 24周SALT≤20应答的利特昔替尼治疗患者中,≥85%维持应答至48周。
- 24周SALT≤10应答的利特昔替尼治疗患者中,≥68%维持应答至48周。
- 24周SALT>20的患者中,22%至34%在48周达到SALT≤20。
- 24周SALT>10的患者中,20%至26%在48周达到SALT≤10。
- 各亚组安全性相似。
关键数值与推荐
- 持续应答定义为24周SALT≤20或≤10应答维持至48周。
- 24周未达标者评估48周达到SALT≤20或≤10的比例。
临床怎么用
- 对24周有应答的斑秃患者,继续利特昔替尼治疗可维持疗效至48周。
- 对24周未达标的患者,继续治疗至48周仍可能获得应答,最多约三分之一可达标。
局限性
- 样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few treatments for alopecia areata have demonstrated sustained efficacy. OBJECTIVE: Evaluate the efficacy and safety of continued ritlecitinib treatment to week 48 in patients with alopecia areata with or without target efficacy responses at week 24. METHODS: Patients aged ≥12 years received daily ritlecitinib (±4-week loading dose): 200/50 mg, 200/30 mg, 50 mg, or 30 mg. Patients with clinical response at week 24, based on a Severity of Alopecia Tool (SALT) score ≤20 and ≤10, were evaluated for sustained response through week 48. Nonresponders at week 24 were assessed for response through week 48. RESULTS: Among ritlecitinib-treated patients with SALT score ≤20 and ≤10 responses at week 24, ≥85% and ≥68%, respectively, sustained these responses through week 48. Of those with a SALT score >20 at week 24, 22% to 34% achieved a SALT score ≤20 at week 48. Of those with a SALT score >10 at week 24, 20% to 26% achieved a SALT score ≤10 at week 48. Safety was similar across subgroups. LIMITATIONS: Small sample size. CONCLUSION: Hair regrowth was sustained through week 48 in patients with response at week 24. Up to one-third of patients who did not meet target efficacy at week 24 achieved response with continued ritlecitinib treatment.
引用
- Piliang M, Lynde C, King B, et al. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial. J Am Acad Dermatol. 2024. PMID: 39423930. doi:10.1016/j.jaad.2024.09.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。